Exploring the competitive inhibition of α-glucosidase by citrus pectin enzymatic hydrolysate and its mechanism: An integrated experimental and simulation approach

Article

作者: Liu, Mingqi ; Zhang, Keer ; Qi, Xinyu ; Li, Nuo ; Wang, Qian ; Feng, Ningxin ; Wang, Yuzhu ; Ouyang, Xingyu

The endo-polygalacturonase D (PgaD) from Aspergillus niger JL15 was recombinantly expressed in Escherichia coli BL21, exhibiting an optimal activity at 55 °C and pH 4.0. Hydrolysis products of citrus pectin by recombinant PgaD included galacturonic acid (GalA), digalacturonic acid (GalA2), trigalacturonic acid (GalA3), and tetragalacturonic acid (GalA4). The hydrolysates exhibited significant antioxidant capacity and dose-dependent competitive inhibition of α-glucosidase. GalA2 and GalA3 acted as competitive inhibitors of α-glucosidase, with inhibition constant of 0.0589 mmol.L^-1 and 0.6732 mmol.L^-1, respectively. Molecular dynamics (MD) simulations revealed that both GalA2 and GalA3 penetrated the catalytic pocket of α-glucosidase and formed stable hydrogen bonds with key catalytic residues D352 and D215. The binding free energies of GalA2-α-glucosidase and GalA3-α-glucosidase complexes were - 10.3 ± 0.6 kcal·mol^-1 and -10.8 ± 0.7 kcal·mol^-1, respectively. These findings might offer new ideas for the development of α-glucosidase inhibitors sourced from citrus pectin, as well as enhance utilization of the renewable plant polysaccharide resources.

2024-12-01·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

New CYP154C4 from Streptomyces cavourensis YBQ59 performs regio- and stereo- selective 3β-hydroxlation of nootkatone

Article

作者: Urlacher, Vlada B. ; Ly, Thuy T B ; Hutter, Michael C ; Thi Mai, Thu-Thuy ; Raffaele, Alessandra ; Hutter, Michael C. ; Ly, Thuy T.B. ; Urlacher, Vlada B ; Nguyen, Thi Thao ; Quach, Tung Ngoc ; Thi Vu, Hanh-Nguyen ; Thuy Le, Duong Thi ; Phi, Quyet-Tien

Nootkatone, a sesquiterpenoid widely used in the food and cosmetics industries, exhibits diverse biological activities and pharmaceutical prospects. Modification of nootkatone to create new derivatives with desirable activities has attracted significant attention. For this purpose, cytochrome P450 monooxygenases (P450 or CYP) are attractive candidates due to their ability to perform regio- and stereoselective hydroxylation at allylic C-H bonds. In this study, CYP154C4 from Streptomyces cavourensis YBQ59 was cloned and expressed in Escherichia coli. By screening 64 candidate substrates, this P450 was found to catalyze the regio- and stereoselective hydroxylation of nootkatone, yielding a single product, 3β-hydroxynootkatone. Using a whole-cell E. coli system expressing CYP154C4, supported by the heterologous redox partners YkuN from Bacillus subtilis and FdR from E. coli, 3β-hydroxynootkatone was produced on a preparative scale. The structure of this compound was determined by ¹H NMR, ¹³C NMR, NOESY, HMBC, and HSQC. The kinetics of product formation were analyzed using HPLC, and the K_m and K_cat values were calculated. Furthermore, structural insights into the selective hydroxylation of nootkatone were elucidated by molecular docking. 3β-Hydroxynootkatone, recently synthesized semi-synthetically from nootkatone, has been reported to exhibit a higher insecticidal activity than its parent compound. Additionally, the functionalization of nootkatone with N-acyl-2-aminothiazole at the C3 and C2 positions, yielding an α-glucosidase inhibitor, has also been previously described. Therefore, 3β-hydroxynootkatone has great potential for further research and for synthesizing new derivatives with valuable biological activities for agricultural and medicinal applications.

2024-12-01·BIOORGANIC CHEMISTRY

Rational design of new quinoline-benzimidazole scaffold bearing piperazine acetamide derivatives as antidiabetic agents

Article

作者: Irajie, Cambyz ; Bagherian Khouzani, Nafiseh ; Ghasemi, Mehran ; Dehghan, Maryam ; Mahdavi, Mohammad ; Lotfi Nosood, Yazdanbakhsh ; Iraji, Aida ; Al-Harrasi, Ahmed ; Ali Faramarzi, Mohammad ; Mojtabavi, Somayeh ; Faramarzi, Mohammad Ali

In this study, a series of fifteen compounds (7a-o) based on a quinoline-benzimidazole scaffold bearing piperazine acetamide derivatives were synthesized and evaluated for their potential as α-glucosidase inhibitors, which are important therapeutic agents in the management of type 2 diabetes mellitus. Among the synthesized compounds, 7m exhibited the most potent inhibitory activity, demonstrating a 28-fold greater efficacy than the standard clinical inhibitor, acarbose. Molecular docking studies indicated strong binding interactions between 7m and the α-glucosidase active site, including hydrogen bonding, π-π stacking, and π-cation interactions. Furthermore, molecular dynamics simulations revealed that compound 7m formed a highly stable complex with the enzyme. These findings suggest that compound 7m is a promising candidate for further development as an effective antidiabetic agent, offering valuable insights into the design of potent α-glucosidase inhibitors based on the quinoline-benzimidazole framework.

项与 Alpha-glucosidase inhibitor(Huadong Medicine) 相关的新闻（医药）

2024-07-15

·drugs

Some Diabetes Drugs May Lower Dementia Risk

MONDAY, July 15, 2024 -- Some diabetes drugs appear to lower the risk that people with type 2 diabetes will develop dementia or Alzheimer’s disease, a new evidence review says. The risk of dementia and Alzheimer’s is significantly lower in patients treated with metformin or a class of meds called "sodium glucose co-transporter-2 (SGLT-2) inhibitors", compared with other diabetes drugs, researchers report. Type 2 diabetes affects about 530 million people around the world, and there’s at least a 50% increased risk of cognitive impairment and dementia in these people, researchers said in background notes. “Our study contributes to the existing evidence by suggesting potential additional benefits of SGLT-2 inhibitors in mitigating dementia risk, thereby providing significant clinical implications for diabetes management,” lead researcher Yeo Jin Choi at Kyung Hee University in Seoul, South Korea, said in a news release. “Elderly patients aged 75 years or older may particularly benefit from these findings, since they often face greater cognitive health concerns,” Choi added. For their review, researchers analyzed data from 16 prior studies involving more than 1.5 million patients. The studies looked at six diabetic drug classes: DPP4 inhibitors, metformin, SGLT-2 inhibitors, sulfonylureas, alpha-glucosidase inhibitors and thiazolidinediones. The lowest risk of dementia and Alzheimer’s was found in patients taking metformin, results show. But SGLT-2 inhibitors were also associated with a lower risk of cognitive decline as well, and also provided heart health benefits, researchers said. These drugs include Farxiga (dapagliflozin) and Jardiance (empagliflozin). What's more, results show that SGLT-2 inhibitors performed better than all other drugs, including metformin, in reducing dementia risk in patients 75 and older. “We were quite surprised by the study results, particularly the potential cognitive benefits of SGLT-2 inhibitors over metformin and DPP-4 inhibitors in patients aged 75 years or older,” Choi said. “This finding is particularly notable given that SGLT-2 inhibitors are currently used for heart failure management as well.” Metformin works by decreasing the amount of glucose produced by the liver and by making muscle tissue more sensitive to insulin, the American Diabetes Association says. SGLT-2 inhibitors increase the amount of glucose that is excreted in urine, lowering blood sugar levels, the ADA says. The new study appears in the American Journal of Preventive Medicine . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2022-12-20

·PRNewswire

DelveInsight Estimates a Promising Picture of Obesity Pipeline Space Landscape as Key 100+ Pharma Companies Working in the Space

The prevalence of obesity has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Obesity and the growing research and development activities to develop novel therapies to treat obesity drive the market. The Companies developing the potential therapies in the last stage of development include Novo Nordisk, Eli Lilly and Company, Saniona, and several others. LAS VEGAS, Dec. 20, 2022 /PRNewswire/ -- DelveInsight's ' Obesity Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline obesity therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obesity pipeline domain. Key Takeaways from the Obesity Pipeline Report DelveInsight's obesity pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for obesity treatment. Key obesity companies such as 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others are evaluating new drugs for obesity to improve the treatment landscape. Promising obesity pipeline therapies in various stages of development include Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others. In December 2022, Amgen announced new Phase I data from AMG 133. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708). The MAD cohorts showed mean percent changes in body weight (BW), ranging from -7.2% at the lowest dose (140mg Q4W), to -14.5% at the highest dose (420mg Q4W) by day 85. A substantial degree of weight loss was maintained beyond the treatment period, which will be shared as part of the oral presentation. Most treatment-emergent adverse events (TEAEs) were mild and transient. The majority of the TEAEs were GI-related, with the most common being nausea and vomiting, most events resolved within 48 hours. In December 2022, Poolbeg Pharma, a clinical-stage infectious disease company, acquired the exclusive license from InsuCaps to use its proprietary microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes, and diabetes. In November 2022, Rhythm Pharmaceuticals, Inc. announced that Great Britain's Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older. In November 2022, Reviva Pharmaceuticals Holdings, Inc. announced the issuance of a patent covering the composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, related co-morbid conditions, and depression and related co-morbid conditions. In October 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity or overweight with weight-related comorbidities. In September 2022, Rivus Pharmaceuticals Inc. announced the completion of a USD 132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. This financing will further support the clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease. In June 2022, LG Chem's new drug for treating genetic obesity received additional ODD (Orphan Drug Designation) from the US FDA. LG Chem announced on the 16th that the FDA recently granted ODD to ' LB54640' for the treatment of 'POMC (Proopiomelanocortin) deficiency.' In April 2022, Saniona announced that it paused the Phase IIb clinical trials testing Tesomet for people with Prader–Willi syndrome (PWS) and hypothalamic obesity (HO). The decision "is not related to the safety or efficacy of Tesomet and is entirely due to funding limitations. The company also announced a reprioritization and restructuring effort to immediately reduce operating expenses while maximizing cash resources. Request a sample and discover the recent advances in obesity drug treatment @ Obesity Pipeline Report The obesity pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage obesity drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obesity clinical trial landscape. Obesity Overview Obesity is a chronic disease that causes abnormal or excessive fat accumulation or adipose tissue in the body, posing a health risk. It is caused by an imbalance between calories consumed and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive fat, sugar consumption (energy-dense meals), certain medications, and endocrine issues. Changes in the environment or society, as well as in behavior and culture, all directly impact. Obesity symptoms go beyond an increase in body fat. It can cause skin issues, shortness of breath, sleeping difficulties, and other symptoms. Some obesity symptoms have even been linked to an increased risk of developing certain diseases and disorders. In some cases, these can be life-threatening or even fatal. Find out more about drugs for obesity @ FDA-approved Obesity Drugs A snapshot of the Obesity Pipeline Drugs mentioned in the report: Learn more about the emerging obesity pipeline therapies @ Obesity Clinical Trials Obesity Therapeutics Assessment The obesity pipeline report proffers an integral view of obesity emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Obesity Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Glucagon like peptide 1 receptor agonists, Gastric inhibitory polypeptide receptor agonists, Beta 1 adrenergic receptor antagonists, Biogenic monoamine uptake inhibitors, Lipolysis modulators, Alpha-glucosidase inhibitors, Amylase inhibitors, Lipase inhibitors, Glucagon like peptide 1 receptor agonists, Glucagon receptor agonists, Islet amyloid polypeptide replacements Key Obesity Companies: 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others. Key Obesity Pipeline Therapies: Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others. Dive deep into rich insights for new drug for obesity treatment; visit @ Obesity Medications Table of Contents For further information on the obesity pipeline therapeutics, reach out @ Obesity Drug Treatment Related Reports Obesity Epidemiology Forecast Obesity Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the obesity epidemiology trends. Obesity Market Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, among others. Hypothalamic Obesity Market Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others. Hypothalamic Obesity Pipeline Hypothalamic Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, among others. HET Obesity/POMC Deficiency Obesity Pipeline HET Obesity/POMC Deficiency Obesity Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others. HET Obesity/POMC Deficiency Obesity Market HET Obesity/POMC Deficiency Obesity Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HET obesity/POMC deficiency obesity companies, including Novo Nordisk, Eli Lilly, and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, among others. Other Trending Reports Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market Related Healthcare Blogs Obesity: A Global Concern Weight Loss and Obesity Market Obesity Treatment Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

临床1期孤儿药快速通道临床2期引进/卖出

2022-11-01

·PRNewswire

Phosphodiesterase (PDE) Inhibitors Market to Grow by USD 2.86 Bn, 40% of Market Growth to Originate from North America - Technavio

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- The phosphodiesterase (PDE) inhibitors market size is expected to grow by USD 2.86 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.81% during the forecast period. The market has been segmented by application (oral, topical, and other ROA) and geography (North America, Europe, Asia, and Rest of World (ROW)). Find a comprehensive report summary that describes the market size and forecast along with the research methodology. The FREE sample report is available in PDF format Continue Reading Technavio has announced its latest market research report titled Global Phosphodiesterase (PDE) Inhibitors Market 2022-2026 Phosphodiesterase (PDE) Inhibitors Market: Segmentation Analysis By geography, North America will lead the thermostatic radiator valve market during the forecast period. The region will account for 40% of the market's growth. The increased consumption of alcohol, tobacco, and adoption of urban lifestyle are the major factors that are contributing to the increased patient pool with lifestyle-related diseases, and thus driving the PDE inhibitors market growth in the region during the forecast period. Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed annually at USD 5000 By application, the oral segment will be the largest contributor to market growth during the forecast period. The oral segment is dominated by PDE inhibitors formulated in tablet dosage forms. Tablets are the most commonly used solid dosage forms, owing to their advantages and increasing popularity. The rising prevalence of various chronic diseases will ensure the continuous adoption of oral PDE inhibitors for their treatment, which would drive segment growth in the coming years. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Buy Now to gain access to detailed information about each segment Phosphodiesterase (PDE) Inhibitors Market: Driver and Trend One of the key factors driving the global phosphodiesterase inhibitors industry growth is the growing adoption of poor lifestyle habits, leading to chronic diseases. As per the CDC, excessive alcohol consumption accounts for approximately 88,000 deaths every year in the US. Working adults aged between 20 and 64 years account for 1 in 10 deaths due to excessive alcohol intake. CDC also estimates that nearly 2,000 people smoke their first cigarette before the age of 18 years. Of these, more than 300 people become daily cigarette smokers. Cigarette smoking is responsible for more than 480,000 deaths every year, including 41,000 deaths due to second-hand smoke. Other factors such as rapid urbanization and modernization have further led to the adoption of poor lifestyle habits, which will further increase the risk, thereby, driving the market growth. The application of novel technologies for PDE inhibitors development is one of the key phosphodiesterase inhibitors market trends that is expected to impact the industry positively in the forecast period. PDE5 enzymes have an amino acid sequence and molecular structure similar to PDE6 and PDE11 and, hence, first-generation PDE5 inhibitors, such as sildenafil and vardenafil, are also competitive inhibitors of PDE6 and PDE11. The application of novel technologies for the development of PDE5 inhibitors is required to decrease their cross-reactivity with PDE6 and PDE11 enzymes. A similarity-based virtual screening technique, such as ZINC database, is used for this. In addition, PDE5 inhibitors, such as tadalafil, are known to block the potassium (K)-dependent HERG1 channel, the cardiac toxicity of the drug was tested through this database. The results thus obtained are of immense importance for researchers to design and develop novel, selective, and safe PDE5 inhibitors, which will further support the market growth. Identify key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report Related Reports: Alpha Glucosidase Inhibitors Market by Disease Type and Geography – Forecast and Analysis 2022-2026: The alpha-glucosidase inhibitors market share is expected to increase by USD 567.96 million from 2021 to 2026. Hedgehog Pathway Inhibitors Market by Indication and Geography – Forecast and Analysis 2022-2026: The hedgehog pathway inhibitors market share is expected to increase by USD 385.52 million from 2021 to 2026. Table of Contents: 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Application Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market Definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Application 5.1 Market segments Exhibit 24: Chart on Application - Market share 2021-2026 (%) Exhibit 25: Data Table on Application - Market share 2021-2026 (%) 5.2 Comparison by Application Exhibit 26: Chart on Comparison by Application Exhibit 27: Data Table on Comparison by Application 5.3 Oral - Market size and forecast 2021-2026 Exhibit 28: Chart on Oral - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Oral - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Oral - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Oral - Year-over-year growth 2021-2026 (%) 5.4 Topical - Market size and forecast 2021-2026 Exhibit 32: Chart on Topical - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Topical - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Topical - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Topical - Year-over-year growth 2021-2026 (%) 5.5 Other ROA - Market size and forecast 2021-2026 Exhibit 36: Chart on Other ROA - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Other ROA - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Other ROA - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Other ROA - Year-over-year growth 2021-2026 (%) 5.6 Market opportunity by Application Exhibit 40: Market opportunity by Application ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 42: Chart on Market share by geography 2021-2026 (%) Exhibit 43: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 44: Chart on Geographic comparison Exhibit 45: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 China - Market size and forecast 2021-2026 Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%) 7.11 Canada - Market size and forecast 2021-2026 Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 Bayer AG Exhibit 89: Bayer AG - Overview Exhibit 90: Bayer AG - Business segments Exhibit 91: Bayer AG - Key offerings Exhibit 92: Bayer AG - Segment focus 10.4 Cristalia laboratory Exhibit 93: Cristalia laboratory - Overview Exhibit 94: Cristalia laboratory - Product / Service Exhibit 95: Cristalia laboratory - Key offerings 10.5 Dong A Socio Holdings Co. Ltd. Exhibit 96: Dong A Socio Holdings Co. Ltd. - Overview Exhibit 97: Dong A Socio Holdings Co. Ltd. - Product / Service Exhibit 98: Dong A Socio Holdings Co. Ltd. - Key offerings 10.6 Dr. Reddys Laboratories Ltd. Exhibit 99: Dr. Reddys Laboratories Ltd. - Overview Exhibit 100: Dr. Reddys Laboratories Ltd. - Business segments Exhibit 101: Dr. Reddys Laboratories Ltd. - Key offerings Exhibit 102: Dr. Reddys Laboratories Ltd. - Segment focus 10.7 Eli Lilly and Co. Exhibit 103: Eli Lilly and Co. - Overview Exhibit 104: Eli Lilly and Co. - Product / Service Exhibit 105: Eli Lilly and Co. - Key offerings 10.8 GlaxoSmithKline Plc Exhibit 106: GlaxoSmithKline Plc - Overview Exhibit 107: GlaxoSmithKline Plc - Business segments Exhibit 108: GlaxoSmithKline Plc - Key news Exhibit 109: GlaxoSmithKline Plc - Key offerings Exhibit 110: GlaxoSmithKline Plc - Segment focus 10.9 Pfizer Inc. Exhibit 111: Pfizer Inc. - Overview Exhibit 112: Pfizer Inc. - Product / Service Exhibit 113: Pfizer Inc. - Key news Exhibit 114: Pfizer Inc. - Key offerings 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 115: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 116: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 117: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Teva Pharmaceutical Industries Ltd. Exhibit 118: Teva Pharmaceutical Industries Ltd. - Overview Exhibit 119: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 120: Teva Pharmaceutical Industries Ltd. - Key news Exhibit 121: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 122: Teva Pharmaceutical Industries Ltd. - Segment focus 10.12 VIVUS LLC Exhibit 123: VIVUS LLC - Overview Exhibit 124: VIVUS LLC - Product / Service Exhibit 125: VIVUS LLC - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 126: Inclusions checklist Exhibit 127: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 128: Currency conversion rates for US$ 11.4 Research methodology Exhibit 129: Research methodology Exhibit 130: Validation techniques employed for market sizing Exhibit 131: Information sources 11.5 List of abbreviations Exhibit 132: List of abbreviations About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio